These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Current trends in immunosuppression following organ transplantation in children. Kim S; Webster AC; Craig JC Curr Opin Organ Transplant; 2013 Oct; 18(5):537-42. PubMed ID: 23995377 [TBL] [Abstract][Full Text] [Related]
9. Differential effects of Belatacept on virus-specific memory versus de novo allo-specific T cell responses of kidney transplant recipients and healthy donors. Kühne JF; Neudörfl C; Beushausen K; Keil J; Malysheva S; Wandrer F; Haller H; Messerle M; Blume C; Neuenhahn M; Schlott F; Hammerschmidt W; Zeidler R; Falk CS Transpl Immunol; 2020 Aug; 61():101291. PubMed ID: 32330566 [TBL] [Abstract][Full Text] [Related]
10. Evolving immunosuppressive regimens for lung transplant recipients. Meyer NJ; Bhorade SM Semin Respir Crit Care Med; 2006 Oct; 27(5):470-9. PubMed ID: 17072795 [TBL] [Abstract][Full Text] [Related]
11. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity. Tönshoff B; Höcker B Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497 [TBL] [Abstract][Full Text] [Related]
12. Immunosuppression in Liver Transplantation: State of the Art and Future Perspectives. Nedredal GI; Picon RV; Chedid MF; Foss A Curr Pharm Des; 2020; 26(28):3389-3401. PubMed ID: 32520679 [TBL] [Abstract][Full Text] [Related]
13. Immunosuppression for lung transplantation: evidence to date. Snell GI; Westall GP Drugs; 2007; 67(11):1531-9. PubMed ID: 17661526 [TBL] [Abstract][Full Text] [Related]
14. Emerging drugs for prevention of T-cell mediated rejection in liver and kidney transplantation. Wong TC; Lo CM; Fung JY Expert Opin Emerg Drugs; 2017 Jun; 22(2):123-136. PubMed ID: 28503959 [TBL] [Abstract][Full Text] [Related]
15. Infectious complications in organ transplant recipients with the use of calcineurin-inhibitor agent-based immunosuppressive regimens. Singh N Curr Opin Infect Dis; 2005 Aug; 18(4):342-5. PubMed ID: 15985832 [TBL] [Abstract][Full Text] [Related]
16. Steroid and calcineurin inhibitor-sparing protocols in kidney transplantation. Helal I; Chan L Transplant Proc; 2011 Mar; 43(2):472-7. PubMed ID: 21440737 [TBL] [Abstract][Full Text] [Related]
17. Recent Advances in Mammalian Target of Rapamycin Inhibitor Use in Heart and Lung Transplantation. Fine NM; Kushwaha SS Transplantation; 2016 Dec; 100(12):2558-2568. PubMed ID: 27495747 [TBL] [Abstract][Full Text] [Related]
18. Impact of different long-term maintenance immunosuppressive therapy strategies on patients' outcome after heart transplantation. Dandel M; Lehmkuhl HB; Knosalla C; Hetzer R Transpl Immunol; 2010 Jul; 23(3):93-103. PubMed ID: 20434559 [TBL] [Abstract][Full Text] [Related]
19. Immunosuppression in the pediatric transplant recipient. Blondet NM; Healey PJ; Hsu E Semin Pediatr Surg; 2017 Aug; 26(4):193-198. PubMed ID: 28964473 [TBL] [Abstract][Full Text] [Related]
20. Belatacept: a novel biologic for maintenance immunosuppression after renal transplantation. Martin ST; Tichy EM; Gabardi S Pharmacotherapy; 2011 Apr; 31(4):394-407. PubMed ID: 21449628 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]